Figure 5.
A. ANO1 expression trend between pre and post imatinib treatment in partial response (PR) plus stable disease (SD) GIST patients. B. ANO1 expression trend between pre- and post-imatinib treatment in progressive disease (PD) GIST patients.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.